AlnylamFor fifteen years, John Maraganore has been the chief executive of Alnylam Pharmaceuticals, working to prove that a technology that directly silences genes could be turned into a drug. So now, before Alnylam’s new drug, patisiran, is even filed with the Food and Drug Administration, Maraganore is making promises about how the company will behave with regard to drug pricing, in a code of conduct being unveiled today at the Forbes Healthcare Summit. The biggest pledge: Alnylam will grow through inventing new medicines, not through large price increases. “We think the most difficult practice to explain to payors and patients is drug price increases. In March, Regeneron and Sanofi announced a price for their new dermatitis drug, Dupixent, with substantial buy-in from the pharmacy benefits manager Express Scripts, normally a critic of new drug prices.

Source: Forbes November 30, 2017 15:00 UTC